Ocular Therapeutix (OCUL) Change in Accured Expenses (2013 - 2026)

Ocular Therapeutix's Change in Accured Expenses history runs 14 years deep, the most recent figure standing at -$8.4 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 64.06% year-over-year to -$8.4 million in Q1 2026; TTM through Mar 2026 was $2.0 million, a 84.41% decrease from a year earlier, with the FY2025 full-year figure at $5.2 million, up 44.26% from the prior year.
• Change in Accured Expenses declined to -$8.4 million in Q1 2026 per OCUL's latest filing, from $2.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $7.9 million in Q2 2024 and bottomed at -$14.0 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1.9 million (2022), against an average of $168352.9.
• Across the five-year window, Change in Accured Expenses surged 930.32% in 2022 and sank 433.9% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.9 million in 2022, then slumped by 164.33% to -$1.2 million in 2023, then jumped by 437.56% to $4.2 million in 2024, then tumbled by 48.26% to $2.2 million in 2025, then plunged by 487.91% to -$8.4 million in 2026.
• Per Business Quant, the three latest OCUL Change in Accured Expenses figures stand at -$8.4 million (Q1 2026), $2.2 million (Q4 2025), and $5.4 million (Q3 2025).